drugset / Trial / NCT03664635
MB-CART20.1 Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.
Timeline
- Start
- 2018-09-25
- Primary completion
- 2024-09-17
- Completion
- 2024-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MB-CART20.1 | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | MB-CART20.1 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | MB-CART20.1 | Cell therapy | 3e+06 cells/kg | Intravenous |